Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a three-dimensional human liver-immunocompetent coculture systems

Drug Metabolism and Disposition

Volumn 45, Issue 7, 2017, Pages 855-866

  Sarkar, Ujjal ^a   Ravindra, Kodihalli C ^a   Large, Emma ^b   Young, Carissa L ^a   Rivera Burgos, Dinelia ^a   Yu, Jiajie ^a   Cirit, Murat ^a   Hughes, David J ^b   Wishnok, John S ^a   Lauffenburger, Douglas A ^a   Griffith, Linda G ^a   Tannenbaum, Steven R ^a,c  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Centre for Innovation and Enterprise   (United Kingdom)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID CONJUGATE; BOVINE SERUM ALBUMIN; COLONY STIMULATING FACTOR 1; DICLOFENAC; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR; ACUTE PHASE PROTEIN; CYTOKINE; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BINDING;

ARTICLE; BIOMICS; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; KUPFFER CELL; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER CELL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TOXIC HEPATITIS; TOXICITY TESTING; BIOLOGICAL MODEL; BIOTRANSFORMATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LIVER; METABOLISM; PROTEOMICS; SECRETION (PROCESS);

ACUTE-PHASE PROTEINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; COCULTURE TECHNIQUES; CYTOKINES; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HUMANS; INFLAMMATION; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEOMICS;

EID: 85020848720     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.116.074005     Document Type: Article

References (45)

1. Axelson M, Ellis E, Mörk B, Garmark K, Abrahamsson A, Björkhem I, Ericzon BG, and Einarsson C (2000) Bile acid synthesis in cultured human hepatocytes: support for an alternative bio-synthetic pathway to cholic acid. Hepatology 31: 1305–1312.
2. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z, and Galon J (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25: 1091–1093.
3. Blum HE (2002) Molecular targets for prevention of hepatocellular carcinoma. Dig Dis 20: 81–90.
4. Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192: 307–322.
5. Bort R, Macé K, Boobis A, Gómez-Lechón MJ, Pfeifer A, and Castell J (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58: 787–796.
6. Brogden RN, Heel RC, Pakes GE, Speight TM, and Avery GS (1980) Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 20: 24–48.
7. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35: 293–301.
8. Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, Griffith LG, and Tannenbaum SR (2009) Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 5: 1159–1174.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093–1095.
10. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519–550.
11. Domansky K, Inman W, Serdy J, Dash A, Lim MH, and Griffith LG (2010) Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10: 51–58.
12. Dutta SK, Basu SK, and Sen KK (2006) Binding of diclofenac sodium with bovine serum albumin at different temperatures, pH and ionic strengths. Indian J Exp Biol 44: 123–127.
13. Ebrahimkhani MR, Neiman JA, Raredon MS, Hughes DJ, and Griffith LG (2014) Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev 69-70: 132–157.
14. Finney DJ (1987) Statistical Method in Biological Assay, 3rd ed, Griffin, London.
15. Fountoulakis M, de Vera MC, Crameri F, Boess F, Gasser R, Albertini S, and Suter L (2002) Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol Appl Pharmacol 183: 71–80.
16. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, et al. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87: 1315–1530.
17. Gómez-Lechón MJ, Donato MT, Castell JV, and Jover R (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 5: 443–462.
18. Granowitz EV, Clark BD, Vannier E, Callahan MV, and Dinarello CA (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79: 2356–2363.
19. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27: 2150–2161.
20. Huang W, Sherman BT, and Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
21. Kegel V, Pfeiffer E, Burkhardt B, Liu JL, Zeilinger K, Nüssler AK, Seehofer D, and Damm G (2015) Subtoxic concentrations of hepatotoxic drugs lead to Kupffer cell activation in a human in vitro liver model: an approach to study DILI. Mediators Inflamm 2015: 640631.
22. Knöspel F, Jacobs F, Freyer N, Damm G, De Bondt A, van den Wyngaert I, Snoeys J, Monshouwer M, Richter M, Strahl N, et al. (2016) In vitro model for hepatotoxicity studies based on primary human hepatocyte cultivation in a perfused 3D bioreactor system. Int J Mol Sci 17: 584.
23. Kostrzewski T, Cornforth T, Snow SA, Ouro-Gnao L, Rowe C, Large EM, and Hughes DJ (2017) Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol 23: 204–215.
24. LeCluyse EL, Witek RP, Andersen ME, and Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42: 501–548.
25. Li AP (2007) Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 168: 16–29.
26. Long TJ, Cosgrove PA, Dunn RT, 2nd, Stolz DB, Hamadeh H, Afshari C, McBride H, and Griffith LG (2016) Modeling therapeutic antibody-small molecule drug-drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab Dispos 44: 1940–1948.
27. Mandrekar P, Ambade A, Lim A, Szabo G, and Catalano D (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 54: 2185–2197.
28. Mehal W and Imaeda A (2010) Cell death and fibrogenesis. Semin Liver Dis 30: 226–231.
29. Messner S, Agarkova I, Moritz W, and Kelm JM (2013) Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 87: 209–213.
30. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, and Seki E (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139: 323–34.e7.
31. Mörk LM, Strom SC, Mode A, and Ellis EC (2016) Addition of dexamethasone alters the bile acid composition by inducing CYP8B1 in primary cultures of human hepatocytes. J Clin Exp Hepatol 6: 87–93.
32. Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, Ayanoglu G, Irrechukwu O, and Evers R (2015) Establishment of a hepatocyte-Kupffer cell co-culture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos 43: 774–785.
33. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350–1359.
34. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283: 46–58.
35. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, and Szabo G (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122: 3476–3489.
36. Ravindra KC, Ho WE, Cheng C, Godoy LC, Wishnok JS, Ong CN, Wong WS, Wogan GN, and Tannenbaum SR (2015) Untargeted proteomics and systems-based mechanistic investigation of artesunate in human bronchial epithelial cells. Chem Res Toxicol 28: 1903–1913.
37. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, and Klaunig JE (2007) Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 96: 2–15.
38. Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, Ebrahimkhani MR, Wishnok JS, Griffith LG, and Tannenbaum SR (2015) Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 43: 1091–1099.
39. Schwarz M, Russell DW, Dietschy JM, and Turley SD (2001) Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J Lipid Res 42: 1594–1603.
40. Skoutakis VA, Carter CA, Mickle TR, Smith VH, Arkin CR, Alissandratos J, and Petty DE (1988) Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm 22: 850–859.
41. Szabo G and Petrasek J (2015) Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 12: 387–400.
42. Tang W (2003) The metabolism of diclofenac–enzymology and toxicology perspectives. Curr Drug Metab 4: 319–329.
43. Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, and Cirit M (2017) Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. J Pharmacol Exp Ther 360: 95–105.
44. Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, Stolz DB, Venkataramanan R, Lauffenburger D, Griffith L, and Wells A (2014) Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer 111: 2342–2350.
45. Zhang Y, Lee P, Liang S, Zhou Z, Wu X, Yang F, and Liang H (2015) Structural basis of nonsteroidal anti-inflammatory drug diclofenac binding to human serum albumin. Chem Biol Drug Des 86: 1178–1184.